Global Cell-Free Circulating Tumor DNA (ctDNA) Market Research Report 2024(Status and Outlook)
Report Overview
Cell-free circulating tumor DNA (ctDNA) can act as a noninvasive cancer biomarker, offering a potential alternative to invasive tissue biopsies.
This report provides a deep insight into the global Cell-Free Circulating Tumor DNA (ctDNA) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Cell-Free Circulating Tumor DNA (ctDNA) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Cell-Free Circulating Tumor DNA (ctDNA) market in any manner.
Global Cell-Free Circulating Tumor DNA (ctDNA) Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Nexomics
Roche
ORIOMICS
Signatera
Illumina
Sysmex Corporation
Bio-Rad
Biocartis
QIAGEN
GuardantHealth
GSK plc
AstraZeneca
NeoGenomics Laboratories
AmoyDx
Annoroad
Burning Rock Biotech
Market Segmentation (by Type)
Gastric Cancer Methylation Screening
Esophageal Cancer Methylation Screening
Colorectal Cancer Methylation Screening
Lung Cancer Methylation Screening
Liver Cancer Methylation Screening
Other Cancer Screening
Market Segmentation (by Application)
Hospital
Medical Center
Laboratory
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Cell-Free Circulating Tumor DNA (ctDNA) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Cell-free circulating tumor DNA (ctDNA) can act as a noninvasive cancer biomarker, offering a potential alternative to invasive tissue biopsies.
This report provides a deep insight into the global Cell-Free Circulating Tumor DNA (ctDNA) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Cell-Free Circulating Tumor DNA (ctDNA) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Cell-Free Circulating Tumor DNA (ctDNA) market in any manner.
Global Cell-Free Circulating Tumor DNA (ctDNA) Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Nexomics
Roche
ORIOMICS
Signatera
Illumina
Sysmex Corporation
Bio-Rad
Biocartis
QIAGEN
GuardantHealth
GSK plc
AstraZeneca
NeoGenomics Laboratories
AmoyDx
Annoroad
Burning Rock Biotech
Market Segmentation (by Type)
Gastric Cancer Methylation Screening
Esophageal Cancer Methylation Screening
Colorectal Cancer Methylation Screening
Lung Cancer Methylation Screening
Liver Cancer Methylation Screening
Other Cancer Screening
Market Segmentation (by Application)
Hospital
Medical Center
Laboratory
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Cell-Free Circulating Tumor DNA (ctDNA) Market
- Overview of the regional outlook of the Cell-Free Circulating Tumor DNA (ctDNA) Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Cell-Free Circulating Tumor DNA (ctDNA) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Cell-Free Circulating Tumor DNA (ctDNA)
1.2 Key Market Segments
1.2.1 Cell-Free Circulating Tumor DNA (ctDNA) Segment by Type
1.2.2 Cell-Free Circulating Tumor DNA (ctDNA) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET OVERVIEW
2.1 Global Market Overview
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET COMPETITIVE LANDSCAPE
3.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Company (2019-2024)
3.2 Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Cell-Free Circulating Tumor DNA (ctDNA) Market Size Sites, Area Served, Product Type
3.4 Cell-Free Circulating Tumor DNA (ctDNA) Market Competitive Situation and Trends
3.4.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Concentration Rate
3.4.2 Global 5 and 10 Largest Cell-Free Circulating Tumor DNA (ctDNA) Players Market Share by Revenue
3.4.3 Mergers & Acquisitions, Expansion
4 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) VALUE CHAIN ANALYSIS
4.1 Cell-Free Circulating Tumor DNA (ctDNA) Value Chain Analysis
4.2 Midstream Market Analysis
4.3 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 Mergers & Acquisitions
5.5.2 Expansions
5.5.3 Collaboration/Supply Contracts
5.6 Industry Policies
6 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2019-2024)
6.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type (2019-2024)
7 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (M USD) by Application (2019-2024)
7.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Application (2019-2024)
8 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET SEGMENTATION BY REGION
8.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region
8.1.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region
8.1.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region
8.2 North America
8.2.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Nexomics
9.1.1 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.1.2 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.1.3 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.1.4 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) SWOT Analysis
9.1.5 Nexomics Business Overview
9.1.6 Nexomics Recent Developments
9.2 Roche
9.2.1 Roche Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.2.2 Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.2.3 Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.2.4 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) SWOT Analysis
9.2.5 Roche Business Overview
9.2.6 Roche Recent Developments
9.3 ORIOMICS
9.3.1 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.3.2 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.3.3 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.3.4 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) SWOT Analysis
9.3.5 ORIOMICS Business Overview
9.3.6 ORIOMICS Recent Developments
9.4 Signatera
9.4.1 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.4.2 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.4.3 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.4.4 Signatera Business Overview
9.4.5 Signatera Recent Developments
9.5 Illumina
9.5.1 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.5.2 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.5.3 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.5.4 Illumina Business Overview
9.5.5 Illumina Recent Developments
9.6 Sysmex Corporation
9.6.1 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.6.2 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.6.3 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.6.4 Sysmex Corporation Business Overview
9.6.5 Sysmex Corporation Recent Developments
9.7 Bio-Rad
9.7.1 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.7.2 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.7.3 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.7.4 Bio-Rad Business Overview
9.7.5 Bio-Rad Recent Developments
9.8 Biocartis
9.8.1 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.8.2 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.8.3 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.8.4 Biocartis Business Overview
9.8.5 Biocartis Recent Developments
9.9 QIAGEN
9.9.1 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.9.2 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.9.3 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.9.4 QIAGEN Business Overview
9.9.5 QIAGEN Recent Developments
9.10 GuardantHealth
9.10.1 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.10.2 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.10.3 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.10.4 GuardantHealth Business Overview
9.10.5 GuardantHealth Recent Developments
9.11 GSK plc
9.11.1 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.11.2 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.11.3 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.11.4 GSK plc Business Overview
9.11.5 GSK plc Recent Developments
9.12 AstraZeneca
9.12.1 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.12.2 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.12.3 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.12.4 AstraZeneca Business Overview
9.12.5 AstraZeneca Recent Developments
9.13 NeoGenomics Laboratories
9.13.1 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.13.2 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.13.3 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.13.4 NeoGenomics Laboratories Business Overview
9.13.5 NeoGenomics Laboratories Recent Developments
9.14 AmoyDx
9.14.1 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.14.2 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.14.3 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.14.4 AmoyDx Business Overview
9.14.5 AmoyDx Recent Developments
9.15 Annoroad
9.15.1 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.15.2 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.15.3 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.15.4 Annoroad Business Overview
9.15.5 Annoroad Recent Developments
9.16 Burning Rock Biotech
9.16.1 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.16.2 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.16.3 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.16.4 Burning Rock Biotech Business Overview
9.16.5 Burning Rock Biotech Recent Developments
10 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) REGIONAL MARKET FORECAST
10.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast
10.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country
10.2.3 Asia Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Region
10.2.4 South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Cell-Free Circulating Tumor DNA (ctDNA) by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Forecast by Type (2025-2030)
11.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Cell-Free Circulating Tumor DNA (ctDNA)
1.2 Key Market Segments
1.2.1 Cell-Free Circulating Tumor DNA (ctDNA) Segment by Type
1.2.2 Cell-Free Circulating Tumor DNA (ctDNA) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET OVERVIEW
2.1 Global Market Overview
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET COMPETITIVE LANDSCAPE
3.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Market Share by Company (2019-2024)
3.2 Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Cell-Free Circulating Tumor DNA (ctDNA) Market Size Sites, Area Served, Product Type
3.4 Cell-Free Circulating Tumor DNA (ctDNA) Market Competitive Situation and Trends
3.4.1 Cell-Free Circulating Tumor DNA (ctDNA) Market Concentration Rate
3.4.2 Global 5 and 10 Largest Cell-Free Circulating Tumor DNA (ctDNA) Players Market Share by Revenue
3.4.3 Mergers & Acquisitions, Expansion
4 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) VALUE CHAIN ANALYSIS
4.1 Cell-Free Circulating Tumor DNA (ctDNA) Value Chain Analysis
4.2 Midstream Market Analysis
4.3 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 Mergers & Acquisitions
5.5.2 Expansions
5.5.3 Collaboration/Supply Contracts
5.6 Industry Policies
6 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Type (2019-2024)
6.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type (2019-2024)
7 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (M USD) by Application (2019-2024)
7.3 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Application (2019-2024)
8 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) MARKET SEGMENTATION BY REGION
8.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region
8.1.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region
8.1.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region
8.2 North America
8.2.1 North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Nexomics
9.1.1 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.1.2 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.1.3 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.1.4 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) SWOT Analysis
9.1.5 Nexomics Business Overview
9.1.6 Nexomics Recent Developments
9.2 Roche
9.2.1 Roche Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.2.2 Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.2.3 Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.2.4 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) SWOT Analysis
9.2.5 Roche Business Overview
9.2.6 Roche Recent Developments
9.3 ORIOMICS
9.3.1 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.3.2 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.3.3 ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.3.4 Nexomics Cell-Free Circulating Tumor DNA (ctDNA) SWOT Analysis
9.3.5 ORIOMICS Business Overview
9.3.6 ORIOMICS Recent Developments
9.4 Signatera
9.4.1 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.4.2 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.4.3 Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.4.4 Signatera Business Overview
9.4.5 Signatera Recent Developments
9.5 Illumina
9.5.1 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.5.2 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.5.3 Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.5.4 Illumina Business Overview
9.5.5 Illumina Recent Developments
9.6 Sysmex Corporation
9.6.1 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.6.2 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.6.3 Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.6.4 Sysmex Corporation Business Overview
9.6.5 Sysmex Corporation Recent Developments
9.7 Bio-Rad
9.7.1 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.7.2 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.7.3 Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.7.4 Bio-Rad Business Overview
9.7.5 Bio-Rad Recent Developments
9.8 Biocartis
9.8.1 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.8.2 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.8.3 Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.8.4 Biocartis Business Overview
9.8.5 Biocartis Recent Developments
9.9 QIAGEN
9.9.1 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.9.2 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.9.3 QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.9.4 QIAGEN Business Overview
9.9.5 QIAGEN Recent Developments
9.10 GuardantHealth
9.10.1 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.10.2 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.10.3 GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.10.4 GuardantHealth Business Overview
9.10.5 GuardantHealth Recent Developments
9.11 GSK plc
9.11.1 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.11.2 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.11.3 GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.11.4 GSK plc Business Overview
9.11.5 GSK plc Recent Developments
9.12 AstraZeneca
9.12.1 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.12.2 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.12.3 AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.12.4 AstraZeneca Business Overview
9.12.5 AstraZeneca Recent Developments
9.13 NeoGenomics Laboratories
9.13.1 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.13.2 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.13.3 NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.13.4 NeoGenomics Laboratories Business Overview
9.13.5 NeoGenomics Laboratories Recent Developments
9.14 AmoyDx
9.14.1 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.14.2 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.14.3 AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.14.4 AmoyDx Business Overview
9.14.5 AmoyDx Recent Developments
9.15 Annoroad
9.15.1 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.15.2 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.15.3 Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.15.4 Annoroad Business Overview
9.15.5 Annoroad Recent Developments
9.16 Burning Rock Biotech
9.16.1 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
9.16.2 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
9.16.3 Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Market Performance
9.16.4 Burning Rock Biotech Business Overview
9.16.5 Burning Rock Biotech Recent Developments
10 CELL-FREE CIRCULATING TUMOR DNA (CTDNA) REGIONAL MARKET FORECAST
10.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast
10.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country
10.2.3 Asia Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Region
10.2.4 South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Cell-Free Circulating Tumor DNA (ctDNA) by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Forecast by Type (2025-2030)
11.2 Global Cell-Free Circulating Tumor DNA (ctDNA) Market Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Cell-Free Circulating Tumor DNA (ctDNA) Market Size Comparison by Region (M USD)
Table 5. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) by Company (2019-2024)
Table 6. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Company (2019-2024)
Table 7. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-Free Circulating Tumor DNA (ctDNA) as of 2022)
Table 8. Company Cell-Free Circulating Tumor DNA (ctDNA) Market Size Sites and Area Served
Table 9. Company Cell-Free Circulating Tumor DNA (ctDNA) Product Type
Table 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Company Market Concentration Ratio (CR5 and HHI)
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. Value Chain Map of Cell-Free Circulating Tumor DNA (ctDNA)
Table 13. Midstream Market Analysis
Table 14. Downstream Customer Analysis
Table 15. Key Development Trends
Table 16. Driving Factors
Table 17. Cell-Free Circulating Tumor DNA (ctDNA) Market Challenges
Table 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (M USD)
Table 19. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (M USD) by Type (2019-2024)
Table 20. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Type (2019-2024)
Table 21. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type (2019-2024)
Table 22. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application
Table 23. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2019-2024) & (M USD)
Table 24. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application (2019-2024)
Table 25. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Application (2019-2024)
Table 26. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2019-2024) & (M USD)
Table 27. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region (2019-2024)
Table 28. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (M USD)
Table 29. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (M USD)
Table 30. Asia Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2019-2024) & (M USD)
Table 31. South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (M USD)
Table 32. Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2019-2024) & (M USD)
Table 33. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 34. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 35. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 36. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) SWOT Analysis
Table 37. Nexomics Business Overview
Table 38. Nexomics Recent Developments
Table 39. Roche Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 40. Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 41. Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 42. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) SWOT Analysis
Table 43. Roche Business Overview
Table 44. Roche Recent Developments
Table 45. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 46. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 47. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 48. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) SWOT Analysis
Table 49. ORIOMICS Business Overview
Table 50. ORIOMICS Recent Developments
Table 51. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 52. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 53. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 54. Signatera Business Overview
Table 55. Signatera Recent Developments
Table 56. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 57. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 58. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 59. Illumina Business Overview
Table 60. Illumina Recent Developments
Table 61. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 62. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 63. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 64. Sysmex Corporation Business Overview
Table 65. Sysmex Corporation Recent Developments
Table 66. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 67. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 68. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 69. Bio-Rad Business Overview
Table 70. Bio-Rad Recent Developments
Table 71. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 72. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 73. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 74. Biocartis Business Overview
Table 75. Biocartis Recent Developments
Table 76. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 77. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 78. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 79. QIAGEN Business Overview
Table 80. QIAGEN Recent Developments
Table 81. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 82. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 83. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 84. GuardantHealth Business Overview
Table 85. GuardantHealth Recent Developments
Table 86. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 87. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 88. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 89. GSK plc Business Overview
Table 90. GSK plc Recent Developments
Table 91. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 92. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 93. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 94. AstraZeneca Business Overview
Table 95. AstraZeneca Recent Developments
Table 96. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 97. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 98. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 99. NeoGenomics Laboratories Business Overview
Table 100. NeoGenomics Laboratories Recent Developments
Table 101. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 102. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 103. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 104. AmoyDx Business Overview
Table 105. AmoyDx Recent Developments
Table 106. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 107. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 108. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 109. Annoroad Business Overview
Table 110. Annoroad Recent Developments
Table 111. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 112. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 113. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 114. Burning Rock Biotech Business Overview
Table 115. Burning Rock Biotech Recent Developments
Table 116. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Region (2025-2030) & (M USD)
Table 117. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2025-2030) & (M USD)
Table 118. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2025-2030) & (M USD)
Table 119. Asia Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Region (2025-2030) & (M USD)
Table 120. South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2025-2030) & (M USD)
Table 121. Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2025-2030) & (M USD)
Table 122. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Type (2025-2030) & (M USD)
Table 123. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Cell-Free Circulating Tumor DNA (ctDNA) Market Size Comparison by Region (M USD)
Table 5. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) by Company (2019-2024)
Table 6. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Company (2019-2024)
Table 7. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-Free Circulating Tumor DNA (ctDNA) as of 2022)
Table 8. Company Cell-Free Circulating Tumor DNA (ctDNA) Market Size Sites and Area Served
Table 9. Company Cell-Free Circulating Tumor DNA (ctDNA) Product Type
Table 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Company Market Concentration Ratio (CR5 and HHI)
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. Value Chain Map of Cell-Free Circulating Tumor DNA (ctDNA)
Table 13. Midstream Market Analysis
Table 14. Downstream Customer Analysis
Table 15. Key Development Trends
Table 16. Driving Factors
Table 17. Cell-Free Circulating Tumor DNA (ctDNA) Market Challenges
Table 18. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Type (M USD)
Table 19. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (M USD) by Type (2019-2024)
Table 20. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Share by Type (2019-2024)
Table 21. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type (2019-2024)
Table 22. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application
Table 23. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Application (2019-2024) & (M USD)
Table 24. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application (2019-2024)
Table 25. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Application (2019-2024)
Table 26. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2019-2024) & (M USD)
Table 27. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region (2019-2024)
Table 28. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (M USD)
Table 29. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (M USD)
Table 30. Asia Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2019-2024) & (M USD)
Table 31. South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (2019-2024) & (M USD)
Table 32. Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Region (2019-2024) & (M USD)
Table 33. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 34. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 35. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 36. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) SWOT Analysis
Table 37. Nexomics Business Overview
Table 38. Nexomics Recent Developments
Table 39. Roche Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 40. Roche Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 41. Roche Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 42. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) SWOT Analysis
Table 43. Roche Business Overview
Table 44. Roche Recent Developments
Table 45. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 46. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 47. ORIOMICS Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 48. Nexomics Cell-Free Circulating Tumor DNA (ctDNA) SWOT Analysis
Table 49. ORIOMICS Business Overview
Table 50. ORIOMICS Recent Developments
Table 51. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 52. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 53. Signatera Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 54. Signatera Business Overview
Table 55. Signatera Recent Developments
Table 56. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 57. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 58. Illumina Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 59. Illumina Business Overview
Table 60. Illumina Recent Developments
Table 61. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 62. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 63. Sysmex Corporation Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 64. Sysmex Corporation Business Overview
Table 65. Sysmex Corporation Recent Developments
Table 66. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 67. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 68. Bio-Rad Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 69. Bio-Rad Business Overview
Table 70. Bio-Rad Recent Developments
Table 71. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 72. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 73. Biocartis Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 74. Biocartis Business Overview
Table 75. Biocartis Recent Developments
Table 76. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 77. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 78. QIAGEN Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 79. QIAGEN Business Overview
Table 80. QIAGEN Recent Developments
Table 81. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 82. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 83. GuardantHealth Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 84. GuardantHealth Business Overview
Table 85. GuardantHealth Recent Developments
Table 86. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 87. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 88. GSK plc Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 89. GSK plc Business Overview
Table 90. GSK plc Recent Developments
Table 91. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 92. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 93. AstraZeneca Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 94. AstraZeneca Business Overview
Table 95. AstraZeneca Recent Developments
Table 96. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 97. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 98. NeoGenomics Laboratories Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 99. NeoGenomics Laboratories Business Overview
Table 100. NeoGenomics Laboratories Recent Developments
Table 101. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 102. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 103. AmoyDx Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 104. AmoyDx Business Overview
Table 105. AmoyDx Recent Developments
Table 106. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 107. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 108. Annoroad Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 109. Annoroad Business Overview
Table 110. Annoroad Recent Developments
Table 111. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Basic Information
Table 112. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Product Overview
Table 113. Burning Rock Biotech Cell-Free Circulating Tumor DNA (ctDNA) Revenue (M USD) and Gross Margin (2019-2024)
Table 114. Burning Rock Biotech Business Overview
Table 115. Burning Rock Biotech Recent Developments
Table 116. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Region (2025-2030) & (M USD)
Table 117. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2025-2030) & (M USD)
Table 118. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2025-2030) & (M USD)
Table 119. Asia Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Region (2025-2030) & (M USD)
Table 120. South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2025-2030) & (M USD)
Table 121. Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Country (2025-2030) & (M USD)
Table 122. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Type (2025-2030) & (M USD)
Table 123. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Industrial Chain of Cell-Free Circulating Tumor DNA (ctDNA)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (M USD), 2019-2030
Figure 5. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (M USD) (2019-2030)
Figure 6. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 8. Evaluation Matrix of Regional Market Development Potential
Figure 9. Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (M USD)
Figure 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Company in 2023
Figure 11. Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 12. The Global 5 and 10 Largest Players: Market Share by Cell-Free Circulating Tumor DNA (ctDNA) Revenue in 2023
Figure 13. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 14. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type
Figure 15. Market Size Share of Cell-Free Circulating Tumor DNA (ctDNA) by Type (2019-2024)
Figure 16. Market Size Market Share of Cell-Free Circulating Tumor DNA (ctDNA) by Type in 2022
Figure 17. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type (2019-2024)
Figure 18. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 19. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application
Figure 20. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application (2019-2024)
Figure 21. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application in 2022
Figure 22. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Application (2019-2024)
Figure 23. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region (2019-2024)
Figure 24. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 25. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country in 2023
Figure 26. U.S. Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 27. Canada Cell-Free Circulating Tumor DNA (ctDNA) Market Size (M USD) and Growth Rate (2019-2024)
Figure 28. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Market Size (Units) and Growth Rate (2019-2024)
Figure 29. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 30. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country in 2023
Figure 31. Germany Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 32. France Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 33. U.K. Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 34. Italy Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 35. Russia Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 36. Asia Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (M USD)
Figure 37. Asia Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region in 2023
Figure 38. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 39. Japan Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 40. South Korea Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 41. India Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 42. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 43. South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (M USD)
Figure 44. South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country in 2023
Figure 45. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 46. Argentina Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 47. Columbia Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 48. Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (M USD)
Figure 49. Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region in 2023
Figure 50. Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 51. UAE Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 52. Egypt Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 53. Nigeria Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 54. South Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 55. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Value (2019-2030) & (M USD)
Figure 56. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share Forecast by Type (2025-2030)
Figure 57. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share Forecast by Application (2025-2030)
Figure 1. Industrial Chain of Cell-Free Circulating Tumor DNA (ctDNA)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (M USD), 2019-2030
Figure 5. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size (M USD) (2019-2030)
Figure 6. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 8. Evaluation Matrix of Regional Market Development Potential
Figure 9. Cell-Free Circulating Tumor DNA (ctDNA) Market Size by Country (M USD)
Figure 10. Global Cell-Free Circulating Tumor DNA (ctDNA) Revenue Share by Company in 2023
Figure 11. Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 12. The Global 5 and 10 Largest Players: Market Share by Cell-Free Circulating Tumor DNA (ctDNA) Revenue in 2023
Figure 13. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 14. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Type
Figure 15. Market Size Share of Cell-Free Circulating Tumor DNA (ctDNA) by Type (2019-2024)
Figure 16. Market Size Market Share of Cell-Free Circulating Tumor DNA (ctDNA) by Type in 2022
Figure 17. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Type (2019-2024)
Figure 18. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 19. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application
Figure 20. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application (2019-2024)
Figure 21. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share by Application in 2022
Figure 22. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Growth Rate by Application (2019-2024)
Figure 23. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region (2019-2024)
Figure 24. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 25. North America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country in 2023
Figure 26. U.S. Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 27. Canada Cell-Free Circulating Tumor DNA (ctDNA) Market Size (M USD) and Growth Rate (2019-2024)
Figure 28. Mexico Cell-Free Circulating Tumor DNA (ctDNA) Market Size (Units) and Growth Rate (2019-2024)
Figure 29. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 30. Europe Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country in 2023
Figure 31. Germany Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 32. France Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 33. U.K. Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 34. Italy Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 35. Russia Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 36. Asia Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (M USD)
Figure 37. Asia Pacific Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region in 2023
Figure 38. China Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 39. Japan Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 40. South Korea Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 41. India Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 42. Southeast Asia Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 43. South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (M USD)
Figure 44. South America Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Country in 2023
Figure 45. Brazil Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 46. Argentina Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 47. Columbia Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 48. Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (M USD)
Figure 49. Middle East and Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size Market Share by Region in 2023
Figure 50. Saudi Arabia Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 51. UAE Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 52. Egypt Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 53. Nigeria Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 54. South Africa Cell-Free Circulating Tumor DNA (ctDNA) Market Size and Growth Rate (2019-2024) & (M USD)
Figure 55. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Size Forecast by Value (2019-2030) & (M USD)
Figure 56. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share Forecast by Type (2025-2030)
Figure 57. Global Cell-Free Circulating Tumor DNA (ctDNA) Market Share Forecast by Application (2025-2030)
